Indeed, depletion of CD8+ or CD4+ T cells abolished the survival extension of CT2A tumor–bearing mice induced by the treatment with cilengitide in combination with WP1066 or AR-A014418 (Figure 6A). The gene discussed is CD8A; the disease is neoplasm.